Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2001-05-30
2003-11-11
Spector, Lorraine (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S069100, C435S320100, C435S325000, C530S300000, C530S350000, C530S399000, C536S023500, C536S024300
Reexamination Certificate
active
06645726
ABSTRACT:
CROSS-REFERENCE TO RELATED APPLICATIONS
Not applicable.
STATEMENT REGARDING FEDERALLY-SPONSORED R&D
Not applicable.
REFERENCE TO MICROFICHE APPENDIX
Not applicable.
FIELD OF THE INVENTION
The present invention is directed to a novel canine DNA sequence encoding the canine growth hormone secretagogue receptor as well as to the protein encoded by that DNA.
BACKGROUND OF THE INVENTION
Growth hormone (GH) is an anabolic hormone capable of promoting linear growth, weight gain and whole body nitrogen retention in mammals. GH is thought to be released primarily from the somatotroph cells of the anterior pituitary. under the coordinate regulation of two hypothalamic hormones, growth hormone releasing factor (GHRF or GRF) and somatostatin. Both GHRF stimulation and somatostatin inhibition of the release of GH occurs by the specific engagement of receptors on the cell membrane of the somatotroph.
GH release is also stimulated by a group of short peptides known as growth hormone releasing peptides (GHRPs) or as growth hormone secretagogues. Among the GHRPs are GHRP-2 (hexarelin) and GHRP-6, which are described, for example, in U.S. Pat. No. 4,411,890, PCT Patent Pub. No. WO 89/07110, PCT Patent Pub. No. WO 89/07111, PCT Patent Pub. No. WO 93/04081, and
J. Endocrinol Invest
., 15 (Suppl 4), 45 (1992). GHRPs function by selectively binding to distinct somatotroph cell membrane receptor(s), the growth hormone secretagogue receptor(s) (GHSRs). A medicinal chemical approach has resulted in the design of several classes of orally-active, low molecular weight, non-peptidyl compounds which bind specifically to human GHSRs and result in the pulsatile release of GH. Such compounds possessing growth hormone secretagogue activity are disclosed, for example, in the following: U.S. Pat. No. 3,239,345; U.S. Pat. No. 4,036,979; U.S. Pat. No. 4,411,890; U.S. Pat. No. 5,206,235; and U.S. Pat. No. 5,283,241.
The use of orally-active agents which engage GHSRs and thus stimulate the pulsatile release of GH has been a significant advance in the treatment of growth hormone deficiency in children and adults and provides substantial benefit under circumstances where the anabolic effects of GH can be exploited clinically (e.g., post-hip fracture rehabilitation, the frail elderly, and in post-operative recovery patients). Other uses for such agents are being discovered from time to time. For example, Copinschi et al. 1997, Neuroendocrinol. 66:278-286 indicates that treatment with the non-peptidyl growth hormone secretagogue MK-677 improves sleep quality.
Provision of GHSRs from non-human species would allow for the development of a new set of agents that could be used as veterinary pharmaceuticals in animal disease states analagous to those described above for humans.
SUMMARY OF THE INVENTION
The present invention is directed to a novel canine DNA that encodes the canine growth hormone secretagogue receptor (GHSR). The DNA encoding canine GHSR is substantially free from other nucleic acids and has the nucleotide sequence shown in SEQ.ID.NO.:1. Also provided is a canine GHSR protein encoded by the novel DNA sequence. The canine GHSR protein is substantially free from other proteins and has the amino acid sequence shown in SEQ.ID.NO.:2. Methods of expressing the canine GHSR protein in recombinant systems and of identifying agonists and antagonists of the canine GHSR are provided.
REFERENCES:
patent: 3239345 (1966-03-01), Hodge et al.
patent: 4036979 (1977-07-01), Asato
patent: 4410513 (1983-10-01), Momany
patent: 4411890 (1983-10-01), Momany
patent: 5057417 (1991-10-01), Hammonds et al.
patent: 5206235 (1993-04-01), Fisher et al.
patent: 5245011 (1993-09-01), Tiberi et al.
patent: 5283241 (1994-02-01), Bochis et al.
patent: 5284841 (1994-02-01), Chu et al.
patent: 5310737 (1994-05-01), Fisher et al.
patent: 5317017 (1994-05-01), Ok et al.
patent: 5374721 (1994-12-01), Schoen et al.
patent: 5422265 (1995-06-01), Civelli et al.
patent: 5430144 (1995-07-01), Schoen et al.
patent: 5434261 (1995-07-01), Schoen et al.
patent: 5438136 (1995-08-01), Devita et al.
patent: 5492916 (1996-02-01), Morriello et al.
patent: 5492920 (1996-02-01), Chen et al.
patent: 5494919 (1996-02-01), Morriello et al.
patent: 5583010 (1996-12-01), Baumbach et al.
patent: 5591641 (1997-01-01), Thorner et al.
patent: 6242199 (2001-06-01), Pui et al.
patent: 6531314 (2003-03-01), Arena et al.
patent: 0 144 230 (1984-03-01), None
patent: 0 513 974 (1992-12-01), None
patent: WO 89/07110 (1989-08-01), None
patent: WO 89/07111 (1989-08-01), None
patent: WO 93/04081 (1993-03-01), None
patent: WO 94/07486 (1994-04-01), None
patent: WO 94/07915 (1994-04-01), None
patent: WO 94/08583 (1994-04-01), None
patent: WO 94/11012 (1994-05-01), None
patent: WO 94/13696 (1994-06-01), None
patent: WO 94/19367 (1994-09-01), None
patent: WO 95/03289 (1995-02-01), None
patent: WO 95/03290 (1995-02-01), None
patent: WO95/09633 (1995-04-01), None
patent: WO 95/11029 (1995-04-01), None
patent: WO 95/12598 (1995-05-01), None
patent: WO 95/13069 (1995-05-01), None
patent: WO 95/14666 (1995-06-01), None
patent: WO 95/16675 (1995-06-01), None
patent: WO 95/16692 (1995-06-01), None
patent: WO 95/17422 (1995-06-01), None
patent: WO 95/17423 (1995-06-01), None
patent: WO 95/34311 (1995-12-01), None
patent: WO 96 02530 (1996-02-01), None
patent: WO 97/21730 (1997-06-01), None
patent: WO 97/22004 (1997-06-01), None
Howard et al., Science, 1996, vol. 273(5277), pp. 974-977.*
Yokote, Ryoji et al. “Molecular Cloning and Gene Expression of Growth Hormone-Releasing Peptide Receptor in Rat Tissues”. Peptides, vol. 19, No. 1, 1998, pp. 15-20.
Muruais, J. et al. “Influence of endogenous cholinergic tone and &agr;-adrenergic pathways on growth hormone responses to His-D-Trp-Ala-D-Phe-Lys-NH2 in the dog”. Journal of Endocrinology, vol. 138, No. 2, 1993, pp. 211-218.
Nelson, Allen H., et al. “Intranasal Activity of the Growth Hormone Releasing Peptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in Conscious Dogs”. Life Sciences, vol. 48, No. 23, 1991, pp. 2283-2288.
Howard, A.D., et al. “A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release”. Science, vol. 273, Aug. 1996, pp. 974-977.
Aloi, J., et al. “Neuroendocrine Responses to a Novel Growth Hormone Secretagogue, L-692, 429, in Healthy Older Subjects”. Journal of Clinical Endocrinology and Metabolism, vol. 79, No. 4, 1994, pp. 943-949.
Bowers, C. “Editorial: On a Peptidomimetic Growth Hormone-Releasing Peptide”. Journal of Clinical Endocrinology and Metabolism, vol. 79, No. 4, 1994, pp. 940-942.
Ok, D., et al. Structure-Activity Relationships of the Non-Peptidyl Growth Hormone Secretagouge L-692, 429, Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 22, 1994, pp. 2709-2714.
Patchett, A., et al. “Design and biological activities of L-163, 191 (MK-0677): A potent, orally active growth hormone secretagogue”. Proc. Natl. Acad. Sci. USA, vol. 92, Jul. 1995, pp. 7001-7005.
Schoen, W., et al. “Chapter 19, Section IV, Growth Hormone Secretagogues”. Annual Reports in Medicinal Chemistry, vol. 28, 1993, pp. 177-183.
Smith, R., et al. “A Nonpeptidyl Growth Hormone Secretagogue”. Science, vol. 260, Jun. 1993, pp. 1640-1643.
Sethumadhavan, K., et al. “Demonstration and Characterization of the Specific Binding of Growth Hormone-Releasing Peptide to Rat Anterior Pituitary and Hypothalamic Membranes”. Biochem. Biophys. Res. Comm., vol. 178, 1991, pp. 31-37.
King, K., et al. “Control of Yeast Mating Signal Transduction by a Mammalian &bgr;2-Adrenergic Receptor and Gs a Subunit”. Science, vol. 250, 1991, pp. 121-123.
Julius, et al. “Molecular Characterization of a Functional cDNA Encoding the Serotonin 1c Receptor”. Science, vol. 241, 1998. pp. 558-564.
Cubitt, et al. “Understanding improving and using green flourescent proteins”. Trends Biochem. Sci., vol. 20, 1995, pp. 448-455.
McKee, K., et al. “Molecular Analysis of Rat Pituitary and Hypothalamic Growth Hormone Secretagogue Receptors”. Molecular Endocrinology, vol. 11, 1997, pp. 415-423.
Feighner, S., et al. “Structural Requirements for the Activation of the Human Growth Hormone
Howard Andrew D.
Palyha Oksana C.
Smith Roy G.
Tan Carina P.
Andres Janet L.
Chisholm Patricia
Spector Lorraine
Tribble Jack L.
LandOfFree
Canine growth hormone secretagogue receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Canine growth hormone secretagogue receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Canine growth hormone secretagogue receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3180164